CHRS vs. TSLY

Last updated Apr 2, 2026

Compare and contrast key facts about Coherus BioSciences, Inc. (CHRS) and YieldMax TSLA Option Income Strategy ETF (TSLY).

TSLY is an actively managed fund by YieldMax. It was launched on Nov 22, 2022.

Performance

CHRS vs. TSLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Coherus BioSciences, Inc. (CHRS) and YieldMax TSLA Option Income Strategy ETF (TSLY). The values are adjusted to include any dividend payments, if applicable.

CHRS vs. TSLY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
CHRS Coherus BioSciences, Inc.	22.54%	2.90%	-58.56%	-57.95%	20.92%
TSLY YieldMax TSLA Option Income Strategy ETF	-9.03%	13.62%	27.83%	50.69%	-27.02%

Returns By Period

In the year-to-date period, CHRS achieves a 22.54% return, which is significantly higher than TSLY's -9.03% return.

CHRS

• 1D: 2.96%
• 1M: 5.45%
• YTD: 22.54%
• 6M: 7.41%
• 1Y: 115.83%
• 3Y*: -36.64%
• 5Y*: -34.61%
• 10Y*: -22.57%

TSLY

• 1D: 1.73%
• 1M: -3.34%
• YTD: -9.03%
• 6M: -8.46%
• 1Y: 48.24%
• 3Y*: 12.10%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CHRS vs. TSLY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CHRS

CHRS Risk / Return Rank: 78
CHRS Sharpe Ratio Rank: 80
CHRS Sortino Ratio Rank: 78
CHRS Omega Ratio Rank: 74
CHRS Calmar Ratio Rank: 84
CHRS Martin Ratio Rank: 77

TSLY

TSLY Risk / Return Rank: 65
TSLY Sharpe Ratio Rank: 60
TSLY Sortino Ratio Rank: 62
TSLY Omega Ratio Rank: 55
TSLY Calmar Ratio Rank: 86
TSLY Martin Ratio Rank: 62

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CHRS vs. TSLY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Coherus BioSciences, Inc. (CHRS) and YieldMax TSLA Option Income Strategy ETF (TSLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CHRS	TSLY	Difference
Sharpe ratio Return per unit of total volatility	1.32	1.10	+0.22
Sortino ratio Return per unit of downside risk	2.04	1.64	+0.40
Omega ratio Gain probability vs. loss probability	1.24	1.22	+0.03
Calmar ratio Return relative to maximum drawdown	2.92	2.66	+0.26
Martin ratio Return relative to average drawdown	5.23	6.37	-1.13
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CHRS vs. TSLY - Sharpe Ratio Comparison

The current CHRS Sharpe Ratio is 1.32, which is comparable to the TSLY Sharpe Ratio of 1.10. The chart below compares the historical Sharpe Ratios of CHRS and TSLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CHRS	TSLY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.32	1.10	+0.22
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.41	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.30	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.21	0.26	-0.47

Correlation

The correlation between CHRS and TSLY is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CHRS vs. TSLY - Dividend Comparison

CHRS has not paid dividends to shareholders, while TSLY's dividend yield for the trailing twelve months is around 95.99%.

	TTM	2025	2024	2023
CHRS Coherus BioSciences, Inc.	0.00%	0.00%	0.00%	0.00%
TSLY YieldMax TSLA Option Income Strategy ETF	95.99%	91.19%	82.30%	76.47%

Drawdowns

CHRS vs. TSLY - Drawdown Comparison

The maximum CHRS drawdown since its inception was -98.21%, which is greater than TSLY's maximum drawdown of -49.52%. Use the drawdown chart below to compare losses from any high point for CHRS and TSLY.

Drawdown Indicators

	CHRS	TSLY	Difference
Max Drawdown Largest peak-to-trough decline	-98.21%	-49.52%	-48.69%
Max Drawdown (1Y) Largest decline over 1 year	-39.56%	-19.82%	-19.74%
Max Drawdown (5Y) Largest decline over 5 years	-96.47%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-97.88%	—	—
Current Drawdown Current decline from peak	-95.36%	-14.94%	-80.42%
Average Drawdown Average peak-to-trough decline	-63.01%	-20.39%	-42.62%
Ulcer Index Depth and duration of drawdowns from previous peaks	22.09%	8.29%	+13.80%

Volatility

CHRS vs. TSLY - Volatility Comparison

Coherus BioSciences, Inc. (CHRS) has a higher volatility of 22.04% compared to YieldMax TSLA Option Income Strategy ETF (TSLY) at 9.82%. This indicates that CHRS's price experiences larger fluctuations and is considered to be riskier than TSLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CHRS	TSLY	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.04%	9.82%	+12.22%
Volatility (6M) Calculated over the trailing 6-month period	62.94%	24.65%	+38.29%
Volatility (1Y) Calculated over the trailing 1-year period	88.37%	44.25%	+44.12%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	84.15%	46.05%	+38.10%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.98%	46.05%	+28.93%